chartexchange

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

GlobeNewswire Inc. | Oct 14, 2026 7:00 AM EDT

Entrada Therapeutics announces that an independent DMC recommends initiation of Cohort 3 at the top dose of 18 mg/kg in the ELEVATE-44-201 study.

Read original article